<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0535-5133</journal-id>
<journal-title><![CDATA[Investigación Clínica]]></journal-title>
<abbrev-journal-title><![CDATA[Invest. clín]]></abbrev-journal-title>
<issn>0535-5133</issn>
<publisher>
<publisher-name><![CDATA[Instituto de Investigaciones Clínicas "Dr. Américo Negrette", Facultad de Medicina, Universidad del Zulia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0535-51332007000300009</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[On the anticonvulsant activity of kaurenic acid]]></article-title>
<article-title xml:lang="es"><![CDATA[Sobre la actividad anticonvulsiva del ácido kaurénico]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Daló]]></surname>
<given-names><![CDATA[Nelson L]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sosa-Sequera]]></surname>
<given-names><![CDATA[Miriam C]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Usubillaga]]></surname>
<given-names><![CDATA[Alfredo]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidad Centroccidental Lisandro Alvarado School of Veterinary Research Unit Dr. H. Moussatché]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Universidad Centroccidental Lisandro Alvarado School of Medicine Research Unit of Experimental Pharmacology]]></institution>
<addr-line><![CDATA[Barquisimeto ]]></addr-line>
</aff>
<aff id="A03">
<institution><![CDATA[,Universidad de Los Andes Faculty of Pharmacy and Bioanalysis Research Institute]]></institution>
<addr-line><![CDATA[Mérida ]]></addr-line>
<country>Venezuela</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2007</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2007</year>
</pub-date>
<volume>48</volume>
<numero>3</numero>
<fpage>349</fpage>
<lpage>358</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://ve.scielo.org/scielo.php?script=sci_arttext&amp;pid=S0535-51332007000300009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://ve.scielo.org/scielo.php?script=sci_abstract&amp;pid=S0535-51332007000300009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://ve.scielo.org/scielo.php?script=sci_pdf&amp;pid=S0535-51332007000300009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Kaurenic acid [(-)-kaur-16-en-19-oic acid] is a diterpene isolated from the aerial parts of Espeletia semiglobulata, one of 85 species of Espeletiinae found in Venezuela. Its anticonvulsive activity was studied using two different models of experimental seizures: spinal seizures induced by sudden cooling (SSSC) in amphibians and seizures induced by pentylenetetrazol (PTZ) in mice. In SSSC, kaurenic acid (KA) inhibited the tonic hind-limb extension with an ED50 of 2.5 mg/kg. It was 4-fold more potent than known anticonvulsant drugs such as carbamazepine and phenytoin and 100-fold more potent than valproic acid. However, KA as well as valproic acid were ineffective against the clonic phase of SSSC. In the PTZ-induced seizures, KA at doses of 0.625 and 1.25 mg/kg increased the latency of seizure onset and protected against generalized clonic-tonic seizures by 45% and 65%, respectively. The sedative effects of KA had an ED50 of 8.5 mg/kg in mice and 75 mg/kg in amphibians. This work provides experimental evidence supporting the potential value of kaurenic acid as an anticonvulsive drug.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[El ácido kaurénico [(-)-kaur-16-en-19-oic acid] es un diterpeno aislado de las partes aéreas de la planta Espeletia semiglobulata, una de la 85 especies de Espeletiinae encontradas en Venezuela. El efecto anticonvulsivo del ácido kaurénico fue estudiado empleando dos modelos diferentes de convulsiones experimentales: convulsiones espinales inducidas por enfriamiento brusco (SSSC) en anfibios y convulsiones inducidas por pentilenotetrazol (PTZ) en ratones. En SSSC, el ácido kaurénico (KA) inhibió la fase tónica con una ED50 de 2,5 mg/kg. KA fue cuatro veces más potente que anticonvulsivos conocidos tales como carbamazepina y fenitoína y 100 veces más potente que el ácido valproico. Sin embargo, el KA al igual que el ácido valproico, fueron inefectivos contra la fase clónica de las SSSC. En convulsiones inducidas por PTZ en ratones, el KA aumentó la latencia y disminuyó la incidencia de la fase clónica-tónica generalizada de las convulsiones inducidas por PTZ en 45% y 65%, a dosis de 0,62 y 1,25 mg/kg, respectivamente. KA produjo sedación a una dosis efectiva (ED50) de 8,5 mg/kg en los ratones y de 75 mg/kg en anfibios. Este trabajo aporta evidencia experimental que soporta el valor potencial del KA como una droga anticonvulsiva.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Diterpenes]]></kwd>
<kwd lng="en"><![CDATA[kaurenic acid]]></kwd>
<kwd lng="en"><![CDATA[seizure]]></kwd>
<kwd lng="en"><![CDATA[anticonvulsant]]></kwd>
<kwd lng="en"><![CDATA[sudden cooling]]></kwd>
<kwd lng="es"><![CDATA[Diterpenos]]></kwd>
<kwd lng="es"><![CDATA[ácido kaurénico]]></kwd>
<kwd lng="es"><![CDATA[convulsión]]></kwd>
<kwd lng="es"><![CDATA[anticonvulsivo]]></kwd>
<kwd lng="es"><![CDATA[enfriamiento rápido]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[  <BASEFONT SIZE="3">     <P ALIGN="center"> <B><font color="#1f1a17" face="Verdana" size="3">On the anticonvulsant activity of kaurenic acid.&nbsp;</font></B> </P>     <P ALIGN="center"><FONT COLOR="#1f1a17" size="2" face="Verdana"> Nelson L. Dal&#243;</FONT><font face="Verdana"><SUP>  </SUP></font><font size="2"><sup><font COLOR="#1f1a17" face="Verdana">1</font></sup></font><FONT COLOR="#1f1a17" size="2" face="Verdana">, Miriam C. Sosa-Sequera<sup>2</sup> and Alfredo Usubillaga<sup>3</sup>.</FONT></P>     <P ALIGN="justify"><font face="Verdana"><SUP> <FONT COLOR="#1f1a17" size="2">1</FONT></SUP><FONT COLOR="#1f1a17" size="2">Research Unit &#147;Dr. H. Moussatch&#233;&#148;, School of Veterinary. Medicine, <SUP>2</SUP>Research  Unit of Experimental Pharmacology, School of Medicine, Universidad Centroccidental  Lisandro Alvarado, Barquisimeto and <SUP>3</SUP>Research Institute, Faculty of Pharmacy  and Bioanalysis, Universidad de Los Andes (ULA). M&#233;rida, Venezuela. E-mail:  nelsondalo@yahoo.com&nbsp;</FONT></font></P>     <P ALIGN="justify"><font color="#1f1a17" size="2" face="Verdana">Corresponding author: Nelson L. Daló. Universidad Centroccidental Lisandro Alvarado, P.O. Box 722, Barquisimeto 3001A, Venezuela. Telephone: 58-251-2592409, Fax: 58-251-2592404. E-mail: nelsondalo@yahoo.com&nbsp;</font></P>     <P ALIGN="justify"><font face="Verdana"> <B><FONT COLOR="#1f1a17" size="2"> Abstract. </FONT></B> <FONT COLOR="#1f1a17" size="2">  Kaurenic acid [(-)-kaur-16-en-19-oic acid] is a diterpene isolated  from the aerial parts of <I>Espeletia semiglobulata</I>, one of 85 species of  Espeletiinae found in Venezuela. Its anticonvulsive activity was studied  using two different models of experimental seizures: spinal seizures induced  by sudden cooling (SSSC) in amphibians and seizures induced by pentylenetetrazol  (PTZ) in mice. In SSSC, kaurenic acid (KA) inhibited the tonic hind-limb  extension with an ED50 of 2.5 mg/kg. It was 4-fold more potent than known  anticonvulsant drugs such as carbamazepine and phenytoin and 100-fold more  potent than valproic acid. However, KA as well as valproic acid were ineffective  against the clonic phase of SSSC. In the PTZ-induced seizures, KA at doses  of 0.625 and 1.25 mg/kg increased the latency of seizure onset and protected  against generalized clonic-tonic seizures by 45% and 65%, respectively.  The sedative effects of KA had an ED50 of 8.5 mg/kg in mice and 75 mg/kg  in amphibians. This work provides experimental evidence supporting the  potential value of kaurenic acid as an anticonvulsive drug.&nbsp; </FONT></font></P>     <P ALIGN="justify"><font face="Verdana"> <B><FONT COLOR="#1f1a17" size="2"> Key words:&nbsp;</FONT></B><FONT COLOR="#1f1a17" size="2">Diterpenes, kaurenic acid, seizure, anticonvulsant, sudden cooling.&nbsp;</FONT></font></P>     <P ALIGN="center"><B><FONT COLOR="#1f1a17" size="2" face="Verdana">Sobre la actividad anticonvulsiva del &#225;cido kaur&#233;nico.</FONT></B></P>     <P ALIGN="justify"><font face="Verdana"> <B><FONT COLOR="#1f1a17" size="2"> Resumen.</FONT></B> <FONT COLOR="#1f1a17" size="2">  El &#225;cido kaur&#233;nico [(-)-kaur-16-en-19-oic acid] es un diterpeno  aislado de las partes a&#233;reas de la planta <I>Espeletia semiglobulata</I>, una  de la 85 especies de Espeletiinae encontradas en Venezuela. El efecto anticonvulsivo  del &#225;cido kaur&#233;nico fue estudiado empleando dos modelos diferentes de convulsiones  experimentales: convulsiones espinales inducidas por enfriamiento brusco  (SSSC) en anfibios <FONT COLOR="#000000" FACE="Caslon224 Bk BT" SIZE="3">y </FONT>convulsiones inducidas por pentilenotetrazol (PTZ)  en ratones. En SSSC, el &#225;cido kaur&#233;nico (KA) inhibi&#243; la fase t&#243;nica con  una ED50 de 2,5 mg/kg. KA fue cuatro veces m&#225;s potente que anticonvulsivos  conocidos tales como carbamazepina y fenito&#237;na y 100 veces m&#225;s potente  que el &#225;cido valproico. Sin embargo, el KA al igual que el &#225;cido valproico,  fueron inefectivos contra la fase cl&#243;nica de las SSSC. En convulsiones  inducidas por PTZ en ratones, el KA aument&#243; la latencia y disminuy&#243; la  incidencia de la fase cl&#243;nica-t&#243;nica generalizada de las convulsiones inducidas  por PTZ en 45% y 65%, a dosis de 0,62 y 1,25 mg/kg, respectivamente. KA  produjo sedaci&#243;n a una dosis efectiva (ED50) de 8,5 mg/kg en los ratones  y de 75&nbsp;mg/kg en anfibios. Este trabajo aporta evidencia experimental que  soporta el valor potencial del KA como una droga anticonvulsiva.</FONT></font></P>     <P ALIGN="justify"><font face="Verdana"> <B><FONT COLOR="#1f1a17" size="2"> Palabras clave:&nbsp;</FONT></B><FONT COLOR="#1f1a17" size="2">Diterpenos, &#225;cido kaur&#233;nico, convulsi&#243;n, anticonvulsivo, enfriamiento r&#225;pido.&nbsp;</FONT></font></P>     ]]></body>
<body><![CDATA[<P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> Received: 17-05-2006. Accepted: 30-11-2006.&nbsp; </FONT></P>     <P ALIGN="justify"> <B><FONT COLOR="#1f1a17" size="2" face="Verdana"> INTRODUCTION&nbsp; </FONT></B> </P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> An intense search for new antiepileptic agents has been the focus of many  investigators in the last three decades, aiming to treat some types of  generalized clonic-tonic seizures that are resistant to drug therapy. In  this concern, some attention has been gained by diterpenes, a group of  natural products of the terpene class containing 20 carbon atoms and 4  branched methyl groups. This occurred specially after the report that forskolin  prevents pentylenetetrazol (PTZ)-induced seizures (1). This work was published  after the discovery that forskolin, isolated from the root of <I>Coleus forskohlii</I>,  is a potent diterpene activator of adenylate cyclase. Forskolin increases  the intracellular level of cAMP and produces subsequent activation of cAMP-dependent  protein kinases involved in the biological responses to many receptor agonists  (2). However, some studies about the anticonvulsant activity of diterpenes  are contradictory (3-5).&nbsp; </FONT></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> Kaurenic acid [(-)-kaur-16-en-19-oic acid], is a diterpene isolated from  the aerial parts of <I>Espeletia semiglobulata</I> (6). We have previously found  that <I>E semiglobulata</I> is the species from which kaurenic acid (KA) is easily  isolated because its resin is rich in this acid and it contains very little  grandiflorenic acid, a compound which makes purification difficult (7).&nbsp; </FONT></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> KA from different natural sources is under investigation for possible antibacterial  (8), cytotoxicity (9) and anti-inflammatory activities (10). In the course  of several experiments designed to investigate the anti-inflammatory effect  of KA using rats and mice, we noticed that treated animals exhibited some  degree of sedation and somnolence. Since these are common side effects  produced by most antiepileptic drugs, we decided to screen a possible anticonvulsant  activity of KA by using two animal models: a) In amphibians, the spinal  seizure-induced by sudden cooling (SSSC), attributed to release of excitatory  amino acids, glutamate, aspartate and the co-agonist glycine (11, 12),  in which common anticonvulsant drugs are active at a similar dose range  that maximal electroshock seizure model (13); b) in mice, the generalized  seizure induced by the PTZ, a GABA<FONT COLOR="#1f1a17"><SUB>A</SUB> receptor antagonist, used even at high  doses, in the screening of putative drugs with anti-absence activity (14).&nbsp;</FONT> </FONT></P>     <P ALIGN="justify"> <B><FONT COLOR="#1f1a17" size="2" face="Verdana"> MATERIALS AND METHODS&nbsp; </FONT></B> </P>     <P ALIGN="justify"><font face="Verdana"> <B><FONT COLOR="#1f1a17" size="2"> Isolation of kaurenic acid (KA)</FONT></B><FONT COLOR="#1f1a17" size="2">&nbsp;</FONT></font></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> Aerial parts of <I>E. semiglobulata</I>, 30 Kg, <FONT COLOR="#000000" FACE="Caslon224 Bk BT" SIZE="3">was </FONT><FONT COLOR="#1f1a17">collected at P&#225;ramo of Piedras  Blancas, M&#233;rida, Venezuela. The leaves were air dried, grounded and extracted  several times with n-hexane at room temperature. The hexane extract was  concentrated and shaken with a 0.5 N NaOH solution. The aqueous layer,  which contained the sodium salt of KA as an emulsion was filtered in a  B&#252;chner funnel. The solid precipitate was mixed with water, acidified with  diluted HCl and it was shaken with hexane. The KA recovered from the hexane  layer was further purified by flash chromatography over silica gel using  hexane and hexane/diethyl ether (9:1) as solvent. An aliquot of each chromatographic  fraction was methylated and inspected by gas chromatography at 250&#176;C (6).&nbsp;</FONT> </FONT></P>     <P ALIGN="justify"><font face="Verdana"> <B><FONT COLOR="#1f1a17" size="2"> Induction of seizures in amphibians</FONT></B><FONT COLOR="#1f1a17" size="2">&nbsp;</FONT></font></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> Experiments were performed using the isolated spinal cord-hind limb preparation  of South American tropical toads (<I>Bufo marinus</I>) following the technique  previously described (11). Amphibians were captured in the surrounding  areas of the city of Barquisimeto. They were kept in open spaces for 1-2  weeks before used. After pithing, the spinal cord was separated from the  brain at C1 level and kept in its vertebral canal joined to the hind limbs  by the sciatic nerves.&nbsp; </FONT></P>     ]]></body>
<body><![CDATA[<P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> The seizure was induced by placing the isolated spinal cord into a cold  Ringer&#146;s bath maintained at 7&#176;C using a bath circulator (Haake, model FK).  The intensity of the seizure was assessed by recording the contractions  of the gastrocnemius muscle using a myograph type B connected to a physiograph  (Narco Biosystems). The latency of the seizure onset was defined as the  time elapsed between the immersion of the isolated cord into the cold Ringer&#146;s  bath and the visualization of the first clonic muscle contractions. Animals  with similar body weight were selected in order to compare the latencies  for seizure onset. The duration of seizure was determined by measuring  on the recording paper the time from the appearance of the first group  of muscle contractions until all muscle activity ceased. In this model,  the pattern of recorded muscle contractions, latencies and duration of  seizures were compared with common anticonvulsants drugs (13).&nbsp; </FONT></P>     <P ALIGN="justify"><font face="Verdana"> <B><FONT COLOR="#1f1a17" size="2"> Induction of seizures by pentylenetetrazol (PTZ) in mice</FONT></B><FONT COLOR="#1f1a17" size="2">&nbsp;</FONT></font></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> Groups of 40-60 NMRI mice weighing 25 to 35 g were obtained from the Animal  Facility of the Universidad Centroccidental Lisandro Alvarado, Barquisimeto  and were acclimatized for 1 day before used. All experiments were performed  in the morning. A dose of PTZ at 85 mg/kg, i.p. reported to induced convulsions  in 96-98% of the animals was used (15, 16), The latency of the first generalized  clonic seizure, as well as, the number of animal that exhibited generalized  clonic-tonic seizure was noted.&nbsp; </FONT></P>     <P ALIGN="justify"><font face="Verdana"> <B><FONT COLOR="#1f1a17" size="2"> Anticonvulsant effect endpoints</FONT></B><FONT COLOR="#1f1a17" size="2">&nbsp;</FONT></font></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> In amphibians, the evaluation of the anticonvulsant effect was done using  two endpoints: a) abolition of tonic hind limb extension (THE) and b) total  blockade of seizure activity, i.e. no visualization neither of tonic nor  clonic muscle contractions (13), whereas in the i.p. PTZ model the endpoint  was the first episode of continuous generalized clonic-tonic seizure of  fore- and/or hind limbs with loss of the righting reflexes, i.e. animals  fell onto their side (17).&nbsp; </FONT></P>     <P ALIGN="justify"><font face="Verdana"> <B><FONT COLOR="#1f1a17" size="2"> Evaluation of adverse effects</FONT></B><FONT COLOR="#1f1a17" size="2">&nbsp;</FONT></font></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> A general behavioral profile was used to evaluate sedation. In mice, sedation  was noted when exhibited somnolence (decrease in motor activity) and decreased  the righting reflexes, i.e. when mice were placed in their back (U shape)  and delayed more than 5 sec to regain the normal position on their four  feet pad. Motor impairment was present when mice showed weakness of the  hind limbs. Amphibians were considered sedated when exhibited a decreased  in the righting reflexes, i.e. more time to recover their normal position  after animals were placed on their back. Motor impairment was considered  present when animals were unable to walk and jump normally.&nbsp; </FONT></P>     <P ALIGN="justify"><font face="Verdana"> <B><FONT COLOR="#1f1a17" size="2"> Injection of drugs</FONT></B><FONT COLOR="#1f1a17" size="2">&nbsp;</FONT></font></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> KA was dissolved in distilled water at a concentration of 6 mg/mL and stored  in the refrigerator for no more than 2 weeks. In amphibians, KA was injected  into the ventral lymphatic sac (i.l.) and mice were injected i.p. In amphibian,  KA was injected 1 to 17 h before the induction of seizure in order to estimate  its peak effect. Subsequently, in both models KA, was given 4 h before  the induction of seizure. Carbamazepine and phenytoin were purchased from  Sigma (St. Louis, MO); valproic acid from commercial sources (Valpron<FONT COLOR="#1f1a17"><SUP>&#174;</SUP>,  Farma, Caracas, Venezuela) and PTZ from RBI (Natick, MA). Valproic acid  was dissolved in 0.65% saline, while carbamazepine and phenytoin were dissolved  in DMSO plus 0.65% saline. Common anticonvulsants were administered i.l.  1 h before the induction of SSSC. Control amphibians received the respective  solvent and control mice were injected with PTZ dissolved in 0.85% saline.&nbsp;</FONT> </FONT></P>     <P ALIGN="justify"><font face="Verdana"> <B><FONT COLOR="#1f1a17" size="2"> Statistical analysis</FONT></B><FONT COLOR="#1f1a17" size="2">&nbsp;</FONT></font></P>     ]]></body>
<body><![CDATA[<P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> Data for latencies and duration of seizures were analyzed using one way  ANOVA followed by Dunnett&#146;s test compared with control values in the amphibian  model and Student&#146;s &#147;t&#148; test in the PTZ model as suggested (17). A p &lt;  0.05 was considered as significant.&nbsp; </FONT></P>     <P ALIGN="justify"> <B><FONT COLOR="#1f1a17" size="2" face="Verdana"> RESULTS&nbsp; </FONT></B> </P>     <P ALIGN="justify"><font face="Verdana"> <B><FONT COLOR="#1f1a17" size="2"> Isolation of kaurenic acid</FONT></B><FONT COLOR="#1f1a17" size="2">&nbsp;</FONT></font></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> In total, 43 g of KA were obtained from <I>E. semiglobulata</I>  (<a href="#fig1">Fig. 1</a>), its  melting point was 175-178<FONT COLOR="#1f1a17"><SUP>o</SUP>C and the chemical structure is presented in <a href="#fig1">  Fig. 1</a>. The sodium salt of KA was fairly soluble in water; but the solution  often required to be shaken before it was taken into the syringe for injection.</FONT></FONT></P>     <P ALIGN="center"><a name="fig1"><img border="0" src="/img/fbpe/ic/v48n3/art09fig1.gif" width="576" height="315"></a></P>     
<P ALIGN="justify"><font face="Verdana"> <B><FONT COLOR="#1f1a17" size="2"> The spinal seizure-induced by sudden cooling (SSSC)</FONT></B><FONT COLOR="#1f1a17" size="2">&nbsp;</FONT></font></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> In control amphibians the immersion of the isolated spinal cord into a  cold Ringer&#146;s bath induced a typical seizure recorded as muscle contractions  that began with a latency of 84 &#177; 6.7 sec. Initially, it was observed as  very tiny muscle fibrillations or tremors which were visualized, but difficult  to record. After this initial phase, a group of larger clonic muscle contractions  appeared that increased in intensity until a full tonic hind-limb extensions  (THE) was reached. This THE phase lasted 4 to 6 seconds, and it was followed  by a second group of irregular clonic muscle contractions until all activity  ceased. The mean total duration of the SSSC was 12.5 &#177; 4.1 sec (n = 17) (<a href="#fig2">Fig. 2</a>).</FONT></P>     <P ALIGN="center"><a name="fig2"><img border="0" src="/img/fbpe/ic/v48n3/art09fig2.gif" width="576" height="414"></a></P>     
<P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> KA was remarkably effective for abolishing the THE at a dose as low as  0.62 mg/kg (<a href="#fig2">Fig. 2</a>), but total blockade of the clonic phase was not achieved  even when a large dose of 160 mg/kg was given. The best peak effective  time post-KA injection was observed to be at 4 h after injection; however,  the blocking effect of KA could still be observed 17 h post injection (80  mg/kg, n = 4). When compared with common anticonvulsants, KA inhibited  the THE with an ED50 of 2.5 mg/kg; while carbamazepine and phenytoin had  an ED50 of 8.6 and 13.0 mg/kg, respectively (<a href="#fig5">Fig.&nbsp;5</a>). Total blockade of  seizure, (i.e. total depression of the clonic phase), was attained for  carbamazepine and phenytoin with an ED50 of 12 and 16 mg/kg, respectively;  while KA and valproic acid were ineffective even at doses of 160 and 1000  mg/kg, respectively.</FONT></P>     <P ALIGN="center"><a name="fig3"><img border="0" src="/img/fbpe/ic/v48n3/art09fig3.gif" width="575" height="465"></a></P>     
]]></body>
<body><![CDATA[<P ALIGN="center"><a name="fig4"><img border="0" src="/img/fbpe/ic/v48n3/art09fig4.gif" width="578" height="470"></a></P>     
<P ALIGN="center"><a name="fig5"><img border="0" src="/img/fbpe/ic/v48n3/art09fig5.gif" width="579" height="321"></a></P>     
<P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> KA did not alter the latency of seizure onset (i.e. the beginning of muscle  contractions). Similar result was obtained when compared with valproic  acid at 500 mg/kg; but carbamazepine and phenytoin significantly prolonged  the latency at 5 and 10 mg/kg, respectively (<a href="#fig3">Fig. 3</a>).&nbsp; </FONT></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> KA had no activity against duration of the clonic phase of seizure and  a similar effect was found when it was compared with valproic acid at doses  of 50 and 100 mg/kg (<a href="#fig4">Fig. 4</a>); in contrast, carbamazepine and phenytoin  tended to decrease the duration of the clonic phase at 5 mg/kg (<a href="#fig2">Fig. 2</a>).&nbsp; </FONT></P>     <P ALIGN="justify"><font face="Verdana"> <B><FONT COLOR="#1f1a17" size="2"> Seizures induced by PTZ</FONT></B><FONT COLOR="#1f1a17" size="2">&nbsp;</FONT></font></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> In 14% of mice PTZ induced only clonic seizures, without loss of righting  reflexes &nbsp;while generalized clonic-tonic seizure were observed in 86% of  the animals (n = 22). When KA was previously given at doses of 0.62 (n  = 18) and 1.25 (n = 20) mg/kg, KA protected mice against the generalized  clonic-tonic seizure to 45% and 65% of the cases, respectively.&nbsp; </FONT></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> In animals treated with PTZ only the mean latency of seizure onset was  61 &#177; 9 sec. After pretreatment with KA at doses of 0.62 and 1.25 mg/kg  respectively, the mean latency of seizure increased significantly to 291  &#177; 77 sec and 254 &#177; 55 sec (p &lt; 0.05).&nbsp; </FONT></P>     <P ALIGN="justify"><font face="Verdana"> <B><FONT COLOR="#1f1a17" size="2"> Estimation of adverse effects</FONT></B><FONT COLOR="#1f1a17" size="2">&nbsp;</FONT></font></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> In mice, KA at dose of 20 mg/kg, exhibited motor impairment that began  2 min after injection and long lasting signs of sedation (8 to 12 h) were  seen in 70% of animals 30 min after treatment. While in amphibians, the  sedative effect of KA was visible at 80 mg/kg, 30 min after treatment,  but it lasted no more than 2 h (<a href="#fig5">Fig.&nbsp;5</a>).&nbsp; </FONT></P>     <P ALIGN="justify"> <B><FONT COLOR="#1f1a17" size="2" face="Verdana"> DISCUSSION&nbsp; </FONT></B> </P>     ]]></body>
<body><![CDATA[<P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> This work present evidences that KA, a diterpene isolated from <I>E. semiglobulata</I>,  has a potent and remarkable activity against THE of SSSC in tropical toads  and PTZ-induced clonic-tonic seizure in mice. After 4 h of KA administration  the pattern of SSSC, recorded as muscle contractions, was very similar  to that found after 1 h of valproic acid injection, i.e. both drugs abolished  the tonic phase of the SSSCs, but failed to block the clonic phase or to  alter the latency and duration of the clonic phase of SSSC. However, the  action of KA was different from that of carbamazepine and phenytoin, wich  were able to produce a total block of the clonic phase (13).&nbsp; </FONT></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> During SSSC, the THE is seen as a maximal muscle contraction, when into  the spinal cord take place a large and long lasting depolarization accompanied  of repetitive firing of motoneurons, that was recorded physiographically  using the hemisected isolated spinal cord with a sucrose gap recordings  (18). The repetitive firing is effectively abolished by N-methyl-D-aspartate  (NMDA) receptor antagonists, but they only reduce the long lasting depolarization  about one half (18). Furthermore, when NMDA receptor antagonists are injected  and, their effect on SSSC recorded as muscle contraction, we have been  able to see prolonged and weak clonic muscle contractions that last up  to 28 sec (11, 13, 19) These previous findings let us think that KA in  the SSSC model may not be acting as a NMDA receptor antagonist.&nbsp; </FONT></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> PTZ is the most commonly used chemical convulsant acting as GABA<FONT COLOR="#1f1a17"><SUB>A</SUB> receptor  antagonist used to induce seizure in rodents. Several routes of administration  and dosage regimes are used, but the most popular are: a) low PTZ doses  (20-30 mg/kg) that induced absence-like seizure that requires EEG monitoring  which is the major obstacle at these doses (14); b) intermediate subconvulsant  doses of PTZ (40 &#150; 60 mg) are used for investigation of proconvulsant action  of drugs (3, 20) and c)&nbsp;high doses of PTZ (80 &#150; 100 mg/kg, s.c.) which can  induce generalized clonic seizure in all animals (15-17). Even though these  high doses do not meet the criteria for experimental absence seizure, these  clonic seizures are used to screen for anti-absence activity and are reported  to produce recruitment of brainstem circuitry with resultant tonic seizures  (14). After PTZ (85 mg/kg, s.c.) latencies to the onset of seizure was  reported between 60&#150;210 sec (15), but smaller latencies between 40 to 110  sec were observed after PTZ given i.p. in our experiments.&nbsp;</FONT> </FONT></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> Members of the diterpene family have a controversial effect after administration  of GABA<FONT COLOR="#1f1a17"><SUB>A</SUB> receptor antagonists. Whereas, forskolin, has been reported to  prevent PTZ-induced seizures in mice (1) and it protects against bicuculline-induced  convulsions (3); in hippocampal slices, it appears to enhance the generation  of afterdischarges and therefore to be proconvulsant (5). In addition,  sclareol glycol, another diterpene of the labdane family, appears to potentiate  PTZ-induced seizures (20). Whether KA acts as activator of adenylate cyclase,  similar to forskolin, remains to be investigated.&nbsp;</FONT> </FONT></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> In our laboratory KA has shown hypotensive effects that are associated  with the generation of nitric oxide (NO). Indeed, spontaneously hypertensive  rats treated with KA, 20 mg/kg, in the presence and absence of L-N<FONT COLOR="#1f1a17"><SUP>G</SUP>-nitroarginine  methyl ester (L-NAME), a NO synthase (NOS) inhibitor, the vaso-relaxant  effects were suggested to be a NO-mediated event (21). It is not feasible  that KA may be acting as anticonvulsant by a NO generating mechanism, because  the doses needed to produce this effect are 10-fold higher than its anticonvulsant  dose. In addition, the role of NOS inhibitors in seizure activity has a  large variation (22). For instance, the model of PTZ-induce seizure in  mice: it is inhibited by L-NAME (23); but it is neither affected by 7-nitroindazole,  a preferential inhibitor of neuronal NOS nor by N<SUP>G</SUP>-nitro-L-arginine, an  arginine analogue (22).&nbsp;</FONT> </FONT></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> A possible effect of KA on sodium channel acting by a mechanism similar  to carbamazepine and phenytoin could not be ruled out, but these agents  are ineffective (17) or tend to aggravate PTZ-induced absence seizure (14),  on the contrary, valproic acid (16, 17) and KA are effective against PTZ-induced  clonic-tonic seizures.&nbsp; </FONT></P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> In conclusion, this work presents evidence that KA, at a dose relatively  low (ED50 of 2.5 mg/kg), has anticonvulsant effects on the SSSC model,  with a pattern of muscle contractions similar to valproic acid, but more  potent than carbamazepine, phenytoin and valproic acid. Furthermore, it  shows that KA is effective for decreasing PTZ-induced clonic-tonic seizures,  as it was also reported for valproic acid (16). We do not have yet an explanation  for the mechanism of action of KA, but these findings suggest that KA deserves  attention and it should be tested in other animal models of seizures in  order to fully characterize its anticonvulsant antivity.&nbsp; </FONT></P>     <P ALIGN="justify"> <B><FONT COLOR="#1f1a17" size="2" face="Verdana"> ACKNOWLEDGMENTS&nbsp; </FONT></B> </P>     <P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> This work was supported by the Research Council (CDCHT) of the Universidad  Centroccidental Lisandro Alvarado (016-ME-2001). It was presented in an  abstract form at The Annual Meeting of Society for Neurosciences, Program  No 94.19, 2005.&nbsp; </FONT></P>     <P ALIGN="justify"> <B><FONT COLOR="#1f1a17" size="2" face="Verdana"> REFERENCES&nbsp; </FONT></B> </P>     ]]></body>
<body><![CDATA[<!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 1.&nbsp;<B>Sano M, Seto-Ohshima A, Mizutani A</B>. Forskolin suppresses seizure induced  by pentylenetetrazol in mice. Experientia 1984; 40:1271-1272.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150273&pid=S0535-5133200700030000900001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 2.&nbsp;<B>Seamon KB, Padgett W, Daly JW</B>. Forskolin: unique diterpene activator of  adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci  1981; 78: 3363-3367.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150274&pid=S0535-5133200700030000900002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 3.&nbsp;<B>Georgieva J</B>. Effect of diterpene sclareol glycol on convulsive seizures.  Methods Find Exp Clin Pharmacol 1989; 11:335-340.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150275&pid=S0535-5133200700030000900003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 4.&nbsp;<B>Ameri A, Gleitz J, Peter T</B>. Bicuculline-induced epileptiform activity in  rat hippocampal slices: suppression by Aconitum alkaloids. Planta Med 1997;  63: 228-232.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150276&pid=S0535-5133200700030000900004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 5.&nbsp;<B>Higashima M, Ohno K, Koshino Y.</B> Cyclic AMP-mediated modulation of epileptiform  afterdischarge generation in rat hippocampal slices. Brain Res 2002; 949:  157-161.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150277&pid=S0535-5133200700030000900005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 6.&nbsp;<B>Usubillaga A, Capra MC</B>. Chemical constituents of <I>Espeletia semiglobulata.</I>  Fitoterapia 1988; 59:382-384.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150278&pid=S0535-5133200700030000900006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 7.&nbsp;<B>Usubillaga A, Romero M, Aparicio R.</B> Kaurenic acid in Espeletiinae. Acta  Hortic 2003; 597: 129-130.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150279&pid=S0535-5133200700030000900007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 8.&nbsp;<B>Davino SC, Giesbrecht AM, Roque NF.</B> Antimicrobial activity of kaurenoic  acid derivatives substituted on carbon-15. Braz J Med Biol Res 1989; 22:1127-1129.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150280&pid=S0535-5133200700030000900008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 9.&nbsp;<B>Ohkoshi E, Makino M, Fujimoto Y.</B> Studies on the constituents of <I>Mikania  hirsutissima</I> (Compositae). Chem Pharm Bull (Tokyo), 1999; 47: 1436-1438.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150281&pid=S0535-5133200700030000900009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 10.&nbsp;<B>Schwaiger S, Adams M, Seger C, Elimerer EP, Bauer R, Stuppner H</B>. New constituents  of <I>Leontopodium alpinum </I>and their in vitro leukotriene biosynthesis inhibitory  activity. Planta Med 2004; 70:978-985.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150282&pid=S0535-5133200700030000900010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 11.&nbsp;<B>Dal&#243; NL, Larson AA.</B> Spinal seizures evoked by sudden cooling of amphibian  isolated spinal cords: involvement of excitatory amino acids. Cryobiology  1991; 28: 255-267.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150283&pid=S0535-5133200700030000900011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 12.&nbsp;<B>Dal&#243; NL, Bracho GA, Pi&#241;a-Crespo JC</B>. Motor impairment and neuronal damage  following hypothermia in tropical amphibians. Int J Exp Pathol 2007; 88(1):1-7.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150284&pid=S0535-5133200700030000900012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 13.&nbsp;<B>Pi&#241;a-Crespo JC, Dal&#243; NL</B>. Activity of common anticonvulsant drugs on spinal  seizure-induced by sudden cooling. Prog Neuro-Psychopharmacol Biol Psychiatry  2006; 30:1202-1208.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150285&pid=S0535-5133200700030000900013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 14.&nbsp;<B>Cortez MA, Snead OC III</B>. Pharmacologic models of generalized absence seizures  in rodents. In: Pitkanen A, Schwartzkroin PA, Moshe SL, Eds. Model of seizures  and epilepsy, Elsevier Inc, 2006, p 111-126.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150286&pid=S0535-5133200700030000900014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 15.&nbsp;<B>Koella WP</B>. Animal experimental models in the study of antiepileptic drugs.  In. Frey HH, Yanz D, Eds. Handbook of Experimental Pharmacology, Springer,  Berlin, 1985; 74: p 281-339.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150287&pid=S0535-5133200700030000900015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 16.&nbsp;<B>Fisher RS</B>. Animal models of the epilepsies. In: Fisher RS, Coyle JC, Eds.  Neurotransmitter and Epilepsy, Wiley-Liss; 1991, p 61-76.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150288&pid=S0535-5133200700030000900016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 17.&nbsp;<B>Loscher W, Honack D, Fassbender P, Nolting B</B>. The role of technical, biological  and pharmacological factors in the laboratory evaluation of anticonvulsant  drugs. III. Pentyllenetetrazole seizure models. Epilepsy Res 1991; 8:171-189.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150289&pid=S0535-5133200700030000900017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 18.&nbsp;<B>Dal&#243; NL, Hackman JC, Davidoff RA</B>. Motoneuron depolarization, paroxysmal  activity and reflex changes induced by rapid cooling of toad spinal cord.  Comp Biochem Physiol 1995; 112A:517-525.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150290&pid=S0535-5133200700030000900018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 19.&nbsp;<B>Dal&#243; NL, Pi&#241;a-Crespo JC</B>. Ketamine abolishes the tonic phase of the seizures  evoked by sudden cooling of toad isolated spinal cords. Neuropharmacology  1992; 31:509-512.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150291&pid=S0535-5133200700030000900019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 20.&nbsp;<B>Georgieva J, Danchev N</B>. The effect of diterpene sclareol on seizure do  not depend on central benzodiazepine receptors. Methods Find Exp Clin Pharmacol  1990; 12: 679-683.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150292&pid=S0535-5133200700030000900020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 21.&nbsp;<B>Neira N, Usubillaga A, Linarez G, Escobar A, Mujica F, Testa M, Sosa-Sequera  M</B>. Vasorelaxant effect of sodium kaurenate: a possible nitric oxide-releasing  agent (Abstract). Biocell 2003; 27(Suppl. 3):392.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150293&pid=S0535-5133200700030000900021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 22.&nbsp;<B>Wojtal K, Gniatkowska-Nowakowska A, Czuczwar SJ</B>. Is nitric oxide involved  in the anticonvulsant action of antiepileptic drugs?. Polish J. Pharmacol  2003; 55: 535-542.&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150294&pid=S0535-5133200700030000900022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="justify"><FONT COLOR="#1f1a17" size="2" face="Verdana"> 23.&nbsp;<B>Kuputlu I, Uzbay T.</B> L-NAME inhibits pentylenetetrazol and strychnine-induced  seizures in mice. Brain Res 1997; 753:98-101.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1150295&pid=S0535-5133200700030000900023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> ]]></body>
<back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Seto-Ohshima]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mizutani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Forskolin suppresses seizure induced by pentylenetetrazol in mice]]></article-title>
<source><![CDATA[Experientia]]></source>
<year>1984</year>
<volume>40</volume>
<page-range>1271-1272</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seamon]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
<name>
<surname><![CDATA[Padgett]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Daly]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells]]></article-title>
<source><![CDATA[Proc Natl Acad Sci]]></source>
<year>1981</year>
<volume>78</volume>
<page-range>3363-3367</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Georgieva]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of diterpene sclareol glycol on convulsive seizures]]></article-title>
<source><![CDATA[Methods Find Exp Clin Pharmacol]]></source>
<year>1989</year>
<volume>11</volume>
<page-range>335-340</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ameri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gleitz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Peter]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Bicuculline-induced epileptiform activity in rat hippocampal slices: suppression by Aconitum alkaloids]]></article-title>
<source><![CDATA[Planta Med]]></source>
<year>1997</year>
<volume>63</volume>
<page-range>228-232</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higashima]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ohno]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Koshino]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cyclic AMP-mediated modulation of epileptiform afterdischarge generation in rat hippocampal slices]]></article-title>
<source><![CDATA[Brain Res]]></source>
<year>2002</year>
<volume>949</volume>
<page-range>157-161</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Usubillaga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Capra]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Chemical constituents of Espeletia semiglobulata]]></article-title>
<source><![CDATA[Fitoterapia]]></source>
<year>1988</year>
<volume>59</volume>
<page-range>382-384</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Usubillaga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Aparicio]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Kaurenic acid in Espeletiinae]]></article-title>
<source><![CDATA[Acta Hortic]]></source>
<year>2003</year>
<volume>597</volume>
<page-range>129-130</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davino]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Giesbrecht]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Roque]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antimicrobial activity of kaurenoic acid derivatives substituted on carbon-15]]></article-title>
<source><![CDATA[Braz J Med Biol Res]]></source>
<year>1989</year>
<volume>22</volume>
<page-range>1127-1129</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ohkoshi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Makino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fujimoto]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Studies on the constituents of Mikania hirsutissima (Compositae)]]></article-title>
<source><![CDATA[Chem Pharm Bull (Tokyo),]]></source>
<year>1999</year>
<volume>47</volume>
<page-range>1436-1438</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwaiger]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Seger]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Elimerer]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Stuppner]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[New constituents of Leontopodium alpinum and their in vitro leukotriene biosynthesis inhibitory activity]]></article-title>
<source><![CDATA[Planta Med]]></source>
<year>2004</year>
<volume>70</volume>
<page-range>978-985</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daló]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Larson]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Spinal seizures evoked by sudden cooling of amphibian isolated spinal cords: involvement of excitatory amino acids]]></article-title>
<source><![CDATA[Cryobiology]]></source>
<year>1991</year>
<volume>28</volume>
<page-range>255-267</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daló]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Bracho]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Piña-Crespo]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Motor impairment and neuronal damage following hypothermia in tropical amphibians]]></article-title>
<source><![CDATA[Int J Exp Pathol]]></source>
<year>2007</year>
<volume>88</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piña-Crespo]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Daló]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Activity of common anticonvulsant drugs on spinal seizure-induced by sudden cooling]]></article-title>
<source><![CDATA[Prog Neuro-Psychopharmacol Biol Psychiatry]]></source>
<year>2006</year>
<volume>30</volume>
<page-range>1202-1208</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cortez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Snead]]></surname>
<given-names><![CDATA[OC III]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Pharmacologic models of generalized absence seizures in rodents]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Pitkanen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartzkroin]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Moshe]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<source><![CDATA[Model of seizures and epilepsy]]></source>
<year>2006</year>
<page-range>111-126</page-range><publisher-name><![CDATA[Elsevier Inc]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koella]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Animal experimental models in the study of antiepileptic drugs]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Frey]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Yanz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Handbook of Experimental Pharmacology]]></source>
<year>1985</year>
<volume>74</volume>
<page-range>281-339</page-range><publisher-loc><![CDATA[Berlin ]]></publisher-loc>
<publisher-name><![CDATA[Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Animal models of the epilepsies]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Coyle]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurotransmitter and Epilepsy]]></source>
<year>1991</year>
<page-range>61-76</page-range><publisher-name><![CDATA[Wiley-Liss]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loscher]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Honack]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fassbender]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Nolting]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs: III. Pentyllenetetrazole seizure models]]></article-title>
<source><![CDATA[Epilepsy Res]]></source>
<year>1991</year>
<volume>8</volume>
<page-range>171-189</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daló]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Hackman]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Davidoff]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Motoneuron depolarization, paroxysmal activity and reflex changes induced by rapid cooling of toad spinal cord]]></article-title>
<source><![CDATA[Comp Biochem Physiol]]></source>
<year>1995</year>
<volume>112A</volume>
<page-range>517-525</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daló]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Piña-Crespo]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Ketamine abolishes the tonic phase of the seizures evoked by sudden cooling of toad isolated spinal cords]]></article-title>
<source><![CDATA[Neuropharmacology]]></source>
<year>1992</year>
<volume>31</volume>
<page-range>509-512</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Georgieva]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Danchev]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The effect of diterpene sclareol on seizure do not depend on central benzodiazepine receptors]]></article-title>
<source><![CDATA[Methods Find Exp Clin Pharmacol]]></source>
<year>1990</year>
<volume>12</volume>
<page-range>679-683</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neira]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Usubillaga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Linarez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Escobar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mujica]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Testa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sosa-Sequera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Vasorelaxant effect of sodium kaurenate: a possible nitric oxide-releasing agent (Abstract)]]></article-title>
<source><![CDATA[Biocell]]></source>
<year>2003</year>
<volume>27</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>392</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wojtal]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gniatkowska-Nowakowska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Czuczwar]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Is nitric oxide involved in the anticonvulsant action of antiepileptic drugs?]]></article-title>
<source><![CDATA[Polish J. Pharmacol]]></source>
<year>2003</year>
<volume>55</volume>
<page-range>535-542</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuputlu]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Uzbay]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[L-NAME inhibits pentylenetetrazol and strychnine-induced seizures in mice]]></article-title>
<source><![CDATA[Brain Res]]></source>
<year>1997</year>
<volume>753</volume>
<page-range>98-101</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
